Mayo Clinic neuro-oncologist Derek Johnson, M.D. discusses study that shows patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer.